NATCAPSUQ

Natural Capsules Limited

Empty hard gelatin capsules for pharmaceutical and nutraceutical clients

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

naturalcapsules.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹160.45
Market cap
167 Cr
Stock P/E
Loss (TTM EPS ₹-23.91)
P/B
0.75
Dividend yield
0.6%
ROE (FY26)
-7.3%
ROCE (FY26)
-4.9%
Operating margin (FY26)
-10.0%
Debt / equity (FY26)
0.52
OCF / EBITDA (3Y)
81.7%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Natural Capsules makes pharmaceutical capsules, both gelatin and HPMC capsules, for drug companies in India and export markets, and has added an active pharmaceutical ingredient (API) business making steroid APIs such as prednisolone and dexamethasone.

Company snapshot

107thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Concerns
  • ✗Net margin is negative — the company is spending more than it earns right now.
2 more signals from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales38 Cr40 Cr40 Cr39 Cr41 Cr44 Cr45 Cr45 Cr46 Cr38 Cr58 Cr49 Cr
Operating expenses (approx.)32 Cr35 Cr36 Cr35 Cr37 Cr40 Cr41 Cr45 Cr47 Cr40 Cr57 Cr48 Cr
EBITDA5 Cr5 Cr4 Cr4 Cr5 Cr4 Cr4 Cr0.32 Cr-0.88 Cr-2 Cr1 Cr1 Cr
OPM %13.6%11.8%10.2%11.1%10.9%9.7%9.7%0.7%-1.9%-6.2%2.3%2.3%
Other income0.35 Cr0.50 Cr0.92 Cr0.18 Cr0.11 Cr0.11 Cr0.30 Cr0.36 Cr0.16 Cr0.45 Cr0.76 Cr2 Cr
Interest1 Cr1 Cr1 Cr1 Cr2 Cr2 Cr2 Cr3 Cr3 Cr3 Cr3 Cr5 Cr
Depreciation2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr2 Cr4 Cr4 Cr4 Cr4 Cr4 Cr
Profit before tax2 Cr2 Cr1 Cr0.77 Cr0.62 Cr0.50 Cr0.89 Cr-6 Cr-8 Cr-9 Cr-5 Cr-6 Cr
Tax %27.1%32.8%32.2%22.1%199.4%79.0%41.6%8.0%9.2%21.7%2.0%1.5%
Net profit2 Cr1 Cr0.97 Cr0.60 Cr-0.61 Cr0.11 Cr0.52 Cr-6 Cr-7 Cr-7 Cr-5 Cr-6 Cr
EPS (₹)₹1.67₹1.29₹1.31₹0.65₹-0.60₹0.10₹0.13₹-5.40₹-6.76₹-6.88₹-4.82₹-5.55

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales60 Cr62 Cr80 Cr135 Cr172 Cr155 Cr169 Cr187 CrSign in free for the trailing twelve months
Operating expenses (approx.)55 Cr56 Cr69 Cr110 Cr138 Cr136 Cr152 Cr189 CrSign in free for the trailing twelve months
EBITDA5 Cr5 Cr11 Cr25 Cr34 Cr20 Cr18 Cr-2 CrSign in free for the trailing twelve months
OPM %7.9%8.6%13.7%18.8%19.8%12.8%10.4%-0.8%Sign in free for the trailing twelve months
Other income1 Cr0.95 Cr0.73 Cr1 Cr0.57 Cr2 Cr0.70 Cr2 CrSign in free for the trailing twelve months
Interest0.37 Cr0.77 Cr0.37 Cr2 Cr3 Cr5 Cr6 Cr11 CrSign in free for the trailing twelve months
Depreciation3 Cr4 Cr4 Cr5 Cr7 Cr9 Cr9 Cr17 CrSign in free for the trailing twelve months
Profit before tax2 Cr1 Cr9 Cr19 Cr24 Cr8 Cr3 Cr-28 CrSign in free for the trailing twelve months
Tax %6.8%37.2%24.6%28.2%27.2%31.1%77.9%11.7%Sign in free for the trailing twelve months
Net profit2 Cr0.86 Cr7 Cr14 Cr18 Cr6 Cr0.62 Cr-25 CrSign in free for the trailing twelve months
EPS (₹)₹3.08₹1.41₹10.99₹19.56₹18.87₹6.23₹0.22₹-23.84Sign in free for the trailing twelve months
Dividend payout %——5.4%4.5%4.4%16.8%0.0%—Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital6 Cr6 Cr6 Cr7 Cr9 Cr9 Cr10 Cr10 Cr
Reserves49 Cr49 Cr56 Cr76 Cr113 Cr194 Cr223 Cr211 Cr
Borrowings5 Cr6 Cr10 Cr51 Cr97 Cr109 Cr104 Cr114 Cr
Other liabilities13 Cr13 Cr25 Cr31 Cr44 Cr39 Cr58 Cr75 Cr
Total liabilities74 Cr75 Cr97 Cr164 Cr288 Cr377 Cr419 Cr424 Cr
Fixed assets (net)24 Cr24 Cr38 Cr64 Cr95 Cr102 Cr282 Cr273 Cr
CWIP2 Cr2 Cr7 Cr20 Cr88 Cr144 Cr0 Cr4 Cr
Investments5 Cr6 Cr0 Cr0.04 Cr0 Cr3 Cr3 Cr3 Cr
Loans & advances0 Cr0.20 Cr0 Cr0.20 Cr0.20 Cr0 Cr0 Cr0 Cr
Inventories4 Cr5 Cr7 Cr5 Cr9 Cr19 Cr25 Cr26 Cr
Trade receivables0 Cr30 Cr27 Cr26 Cr51 Cr54 Cr62 Cr71 Cr
Cash & bank0.05 Cr0.33 Cr0.10 Cr1 Cr1 Cr2 Cr0.69 Cr0.22 Cr
Other assets38 Cr7 Cr19 Cr47 Cr43 Cr52 Cr46 Cr46 Cr
Total assets74 Cr75 Cr97 Cr164 Cr288 Cr377 Cr419 Cr424 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity2 Cr7 Cr12 Cr1 Cr16 Cr-8 Cr27 Cr11 Cr
Cash from investing-7 Cr-6 Cr-16 Cr-46 Cr-105 Cr-73 Cr-44 Cr-11 Cr
Cash from financing4 Cr-1 Cr3 Cr46 Cr89 Cr82 Cr16 Cr-0.62 Cr
Net cash flow-0.68 Cr0.27 Cr-0.22 Cr1 Cr0.08 Cr0.78 Cr-2 Cr-0.47 Cr
Free cash flow (OCF − Capex)-5 Cr2 Cr-11 Cr-45 Cr-90 Cr-79 Cr-18 Cr-0.61 Cr

Ratios

MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %4.0%3.5%13.3%16.0%11.3%3.9%2.5%-4.9%
ROE %3.5%1.5%11.1%16.8%11.9%2.4%0.2%-7.3%
Debtor days018012271108128134139
Inventory days69696730398310793
Days payable13291165118120132161195
Cash conversion cycle-6315824-1727787937
OCF / EBITDA %44.5%135.6%113.4%4.6%45.5%-42.0%152.7%—
OCF / EBITDA % (3 years)——103.6%49.9%41.3%10.5%47.4%81.7%
Debt / equity0.100.110.160.610.790.530.450.52
Current ratio0.472.101.230.931.501.621.301.03
Net debt / EBITDA1.141.120.871.942.785.365.89—